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additional 6% to 11% of variance), however carer characteristics only emerged as a 
significant predictor of the health burden scale (11% of explained variance). Key indi-
vidual predictor variables of burden domains included patients’ general health sta-
tus, presence of a stoma, and the time costs associated with care. ConClusions: 
These results highlight the need to recognise the role that various factors play in 
determining carer burden. While certain aspects of carer characteristics influence 
this, patient health and care-related activities have the most significant impact 
pointing to a need to deliver effective support to those most at risk of carer burden.
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INvestIgatINg the use of PersoNalIsed MedICINe IN CaNCer trIals – aN 
uPdate
Hamilton K.A., Wilson T.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: Personalised medicine continues to be a hot topic in health care evalu-
ation, particularly in diseases where response to therapy within the patient popula-
tion is often heterogenous. The results of an analysis previously presented at ISPOR 
showed that the proportion of cancer trials investigating personalised medicine 
rose 7-fold between 2000 and 2010. However, in 2011, this trend appeared to have 
reached a plateau, with the proportion of cancer trials considering personalised 
medicine settling at around 15-20%. The aim of this study was to update the previous 
research to take account of the proportion of cancer trials which included personal-
ised medicine between 2012 and 2013, inclusive, to assess whether this pattern has 
changed in more recent years. Methods: Terms including ‘diagnostic’, ‘prognostic’ 
and ‘biomarker’ were used to search ClinicalTrials. gov for all interventional cancer 
trials which started between 2012 and 2013 and considered the use of individualised 
medicine. These trials were then compared to those of all interventional cancer tri-
als listed on ClinicalTrials. gov starting in the same period. Results: Of all cancer 
trials analysed between 2000 and 2013, inclusive, 3,664 of 25,203 (14.5%) consid-
ered personalised medicine. Although the previous analysis showed a substantial 
increase in this proportion between 2000 and 2010, this trend does not appear to 
continue into the current decade. The proportion of trials considering personalised 
medicine identified in this update was consistent with that seen in 2011, with 17.7% 
of trials in 2012 and 18.8% in 2013 considering personalised medicine, perhaps sig-
nifying a lack of further increase in research interest. ConClusions: Surprisingly, 
in spite of the apparent drive and enthusiasm for the use of personalised medicine 
within the medical community, these results indicate that the proportion of such 
trials may have reached a plateau. Therefore, this might suggest that cancer research 
is continuing to focus on traditional, non-personalised interventions.
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exPeCtatIoNs for reCoNstruCted Breast aPPearaNCe
Scott A.M.1, Lawson J.L.2, Mazza M.C.3, Rubin L.R.3
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Yeshiva University, Bronx, NY, 
USA, 3The New School for Social Research, New York, NY, USA
objeCtives: Women who undergo mastectomy, whether due to a first-time breast 
cancer diagnosis or recurrence, are often presented with the option of breast recon-
struction. Decisions whether to undergo reconstruction are informed by women’s 
surgery expectations, which develop based on many factors, including past knowl-
edge and experience. The aim of this study was to examine the impact of previous 
breast cancer diagnosis on a women’s approach to expectation-identification of their 
reconstructed breast appearance. Methods: This study was performed using cross-
sectional data as part of a larger field-test. Expectations scales of the BREAST-Q PRO 
were administered in a clinical setting to breast cancer patients seeking immediate 
breast reconstruction. Responses were categorized into specific (unlikely, somewhat 
likely, very likely) or vague expectations (don’t know) as the dependent variable. The 
independent variable was defined as previous or primary diagnosis. Chi Square and 
one-way ANOVA were performed using SPSS22. Results: The study sample (n = 62; 
response rate, 66%) was characterized by a mean age of 49.6 ± 9.2 years, 82.3% married, 
77.4% employed and 79.0% Caucasian. Twenty-three (37.1%) had a history of previous 
breast cancer diagnosis without mastectomy. Women who had previous breast cancer 
diagnosis were more likely to select a specific expectation in response to what their 
new breast (s) would look like in the mirror clothed (ETA squared; 0.11, P= 0.011) and 
unclothed (ETA squared; 0.09, P= 0.017) one year after reconstruction. ConClusions: 
Expectancies guide perception, so that people tend to focus on events that are congru-
ent with their expectations. In our study, women undergoing breast reconstruction 
were more likely to identify a specific expectation about the appearance of their 
reconstructed breast if they had been previously diagnosed with breast cancer. More 
research is needed to determine additional factors that may mediate the develop-
ment of preoperative surgical expectations. Such information will aid in facilitating 
patient-physician communication.
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objeCtives: To determine how often NICE recommendations are more restric-
tive than market authorizations in oncology reviews compared to non-oncology 
reviews. Methods: 161 NICE Technology Appraisal decisions from 2007-2013 were 
evaluated; 95 non-oncology and 66 oncology reviews. For each generic drug included 
in a review, the corresponding brand and market authorization was retrieved from 
the EMA or MHRA. NICE positive decisions were compared to the market authoriza-
tions. Any decision that included language that restricted the population eligible for 
treatment or reimbursement for a given therapy was categorized as “recommend 
with restrictions.” NICE positive decisions that were not more restrictive than the 
market authorizations were categorized as “recommend.” Negative decisions were 
categorized as “do not recommend.” Results: Oncology reviews were more likely to 
By comparison, only 7/88 (8%) of NICE-approved cancer appraisals have been subject 
to restrictions in addition to the label. ConClusions: Access to anti-cancer drugs 
under the CDF tends to be more restrictive than those approved by NICE. Thus, attain-
ing NICE approval for CDF-approved drugs could broaden clinical access as well as 
ensuring reimbursement after the fund is due to close in 2016. Nevertheless, the CDF 
does provide a formal mechanism under which reimbursement can be provided for 
off-label use of cancer drugs, which NICE will not consider.
PCN257
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objeCtives: To analyse HTA recommendations for cancer drug technologies issued 
by Agency for Health Technology Assessment (AHTAPol) in Poland and to verify if 
official threshold value for cost-effectiveness is respected. Methods: The review 
of HTA recommendations concerning cancer technologies issued by AHTAPol in the 
period from January 2012 to March 2014 was preformed. The classification of HTA 
recommendations based on Raftery’s approach labeling them as positive, positive 
with major or minor restriction and negative was conducted. Decisions and ICURs 
values from each recommendation were compared to the official threshold value for 
cost-effectiveness (in Poland defined as 3xGDP for each year) and defined whether 
the ICUR value is either above or below the official threshold. Other aspects of 
recommendations, such as criterion for decision, type of RSS implemented and 
reasons for restrictions were also analysed. Results: In the studied period AHTAPol 
issued 46 recommendations for 35 different cancer drugs (due to the multiplied 
recommendations for 4 drugs). After review, 32 recommendations with calculated 
ICUR (with Risk Sharing Scheme (RSS) if implemented) were included in the analy-
sis. For 11 of 13 negative recommendations ICUR values were placed above offi-
cial AHTAPol’s threshold. For 7 of 11 positive recommendations ICUR values were 
placed below threshold. On the other hand, for 5 of 7 positive recommendations 
with major restriction ICUR values were placed above official threshold. However, 
restrictions were related to the unacceptable cost-effectiveness. The same analysis 
for the ICUR values without implementation of RSS was conducted to compare the 
results. ConClusions: The official threshold values set in AHTAPol are respected 
in the majority of decisions for cancer drugs. Cost-effectiveness is one of the most 
important criterion of decisions made by AHTAPol. Clinical effectiveness, safety and 
specificity of end-of-life extending medicines were also considered.
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objeCtives: To compare drug prices and public expenditure of out-patient cancer 
drugs between two consecutive periods: reference based pricing (RBP) and public 
tendering at MoH in 2010 and RBP only in a positive drug list (PDL) at the National 
Health Insurance Fund (NHIF) in 2011. Methods: We compared the prices of the 40 
products, which are used in out-patient setting. We used public documents like ten-
der results from 2010 MoH tender and reimbursement list of NHIF in 2011. Results: 
70% of the products (n= 28) were with higher prices, 20% had no price change (n= 8) 
and 10% (n= 4) had lower prices in 2011. In 2010, 15% (n= 6) had 50% lower prices 
than same products’ prices in the PDL in 2011. For 10% of the products (n= 4) in 
2010, after tendering, the MoH paid higher prices than the registered prices after 
RBP. These were patented products, without generic competition. In 2011, NHIF paid 
BGN 18.591.365 for these 40 drugs. For the same quantities, with MoH 2010 prices, 
the public expenditure could be BGN 10.788.430 (42% lower). ConClusions: Public 
tendering achieved lower prices than RBP alone. For patented products, without 
generic competition, tendering is not the ultimate solution. Tendering should be 
used with caution, as it can drive some producers out of the market and create 
non-competitive environment with counter-productive results. Frequent changes 
of the laws and regulations, without budget impact analysis, is like gambling. Long-
term national drug pricing policy is hardly needed and should be strictly followed.
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objeCtives: This study aimed to explore the key determinants of caregiver burden 
in colorectal cancer (CRC) carers. Specifically we analysed the effect of (i) patient 
health (ii) care-related activities, and (iii) carer characteristics, as predictors of four 
distinct aspects of carer burden. Methods: 495 CRC survivors (response rate = 39%) 
diagnosed 2007-2009 completed a questionnaire which collected information on 
socio-demographic characteristics, as well as disease and treatment-related factors. 
General health status was measured using the EORTC QLQ30.228 of these survivors 
indicated that they had informal carers who were then sent a questionnaire includ-
ing questions on socio-demographic factors, health status and care-related costs 
as well as the Caregiver Reaction Assessment (CRA) scale. Hierarchical multiple 
regression analysis was used to assess the impact of patient factors, care-related 
activities and carer characteristics on four burden elements within the CRA (family 
support, finances, schedule, and health). Results: 153 carers completed the carer 
questionnaire and were included in the analysis with their corresponding patients. 
Patient characteristics and disease-related factors were the strongest predictor of 
all four aspects of caregiver burden ranging from 14% to 22% of explained variance. 
Care-related activities also significantly predicted burden scores (explaining an 
